The FDA’s Oncologic Drugs Advisory Committee voted 7 to 2 in favor of atezolizumab plus nab-paclitaxel maintaining its accelerated approval to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.
CancerNetwork’s latest podcast episode dissects and article from the journal ONCOLOGY® focusing on 4 PARP inhibitors investigated for the treatment of advanced prostate cancer.
A phase 2 trial found that acalabrutinib may present a potential therapeutic option for patients with chronic lymphocytic leukemia who discontinued ibrutinib treatment.
Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as therapy for patients with RET-altered advanced solid tumors who were treated on the LIBRETTO-001 trial.
Young women with gastrointestinal cancers who received the FOLFIRI or FOLFOX chemotherapy regimens experienced a benefit in terms of reduced nausea and vomiting with the combination of aprepitant plus palonosetron and dexamethasone.
The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.
Look back at some of the important news and notes from last week in the world of oncology, featuring articles from the latest issue of the Journal ONCOLOGY®.
Data from Nature Communications detailed MutaSeq, a new method for distinguishing between cancer stem cells, mature stem cells, and healthy stem cells in acute myeloid leukemia.
A clinical trial examining the safety of stereotactic body radiotherapy for patients with oligometastases indicated that the modality was safe for patients with multiple metastatic sites.
Combination therapy with tislelizumab/chemotherapy improved progression-free survival and the overall response rate for patients with squamous non–small cell lung cancer when compared with chemotherapy alone.
Marron discussed the next steps to a trial of PGV-001, specifically centered around determining the immunogenicity of vaccinated patients against their antigens.
The study concluded that immune-related adverse events were more common than previously anticipated following adjuvant anti–PD-1 therapy and persisted with prolonged follow-up.
ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.
During an After Hours segment of Medical World News®, Nina Shah, MD, spoke about her new passion for Peloton, the convenience of working out from home, and the importance of getting out of the office for personal health and wellness.
Specific resources needed for survivors of cancer to effectively cope during the first year after treatment were limited due to the COVID-19 pandemic, causing survivors to self-cope with known mechanisms.
A new Chemotherapy Education Policy at an NCCN-designated oncology center was received well by nursing and pharmacy staff, yet failed to meet its goals of better-informing patients about their therapy prior to their first dose.
The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.
Data from the phase 2 LOTIS-2 clinical trial supported the accelerated approval of loncastuximab tesirine for patients with relapsed or refractory large B-cell lymphoma.
A poster presentation from the Oncology Nursing Society’s 46th Annual Congress describes a single-center clinician education program aimed at improving patient satisfaction.
Data on the use of ixazomib plus lenalidomide/dexamethasone were similar to results from the pivotal TOURMALINE-MM1 trial, suggesting patients with multiple myeloma in routine practice could achieve similar outcomes to patients treated on clinical trials.
Even though the trastuzumab/radiotherapy failed to meet the trial-specified reduction threshold, a modest, statistically nonsignificant reduction in ipsilateral breast cancer rates were observed.
As genomic profiling becomes more and more essential as part of clinical decision making, clinicians are challenged to stay abreast of advancements in this space to improve patient outcomes and advance the field of precision oncology.
A recent analysis revealed that patients with cancer who scored highly on depression and anxiety scales were more likely to suffer from symptoms of chemotherapy-induced nausea.
Based on results from the phase 2 GARNET trial, dostarlimab may be used to treat recurrent or advanced endometrial cancer progressing on or after treatment with a platinum-containing chemotherapy that is mismatch repair deficient.
According to the research, there are important components and factors missing from the scale commonly used to measure a clinician’s quality of life.
Experts discusses the treatment of patients with HER2-positive breast cancer in a virtual CancerNetwork® Around the Practice presentation,“Relapsed/Refractory HER2+ Metastatic Breast Cancer,” held January 21, 2021, and moderated by Adam M. Brufsky, MD, PhD.
Scott T. Tagawa, MD, considers data for the novel PSMA-targeted radiopharmaceutical 177Lu-PSMA-617.
Radowan A. Elnair, MD, and Sarah A. Holstein, MD, PhD, review literature regarding progress in the management of the transplant-ineligible multiple myeloma in an article published in the journal ONCOLOGY®.
The 2 pilot multidisciplinary care teams reported positive feedback with the collaboration, explaining that the meetings were valuable to the quality care of their patients.
